Anti-Human IL13 Recombinant Antibody (Lebrikizumab) (CAT#: TAB-219)

Figure 1 Inhibition of IL-13 binding to receptor.

(●) would reduce binding of cytokine to receptor. (a) LebFab does not inhibit binding of biotinylated human IL-13 (60 nM) to human IL-13Rα1. Control anti-IL-13 human IgG (■) reduces binding of biotinylated human IL-13 from a maximum level of cytokine binding (▼) to a level of no cytokine (▲). (b) LebFab does not inhibit binding of biotinylated human IL-13 (0.4 nM) to human IL-13Rα2. Error bars represent ± standard deviation of three independent measurements.

Ultsch, M., Bevers, J., Nakamura, G., Vandlen, R., Kelley, R. F., Wu, L. C., & Eigenbrot, C. (2013). Structural basis of signaling blockade by anti-IL-13 antibody lebrikizumab. Journal of molecular biology, 425(8), 1330-1339.

Figure 2 Allergen‐induced changes in FEV1 following challenges at screening and Week 13.

The allergen‐induced percentage change in FEV1 during screening (a) and at Week 13 (b) in placebo‐ and lebrikizumab‐treated subjects. FEV1 was collected every 10 min for the first 90 min and then every hour from 2 to 8 h following allergen challenge. Data points are means. Vertical bars are standard error of the mean.

Scheerens, H., Arron, J. R., Zheng, Y., Putnam, W. S., Erickson, R. W., Choy, D. F.,... & Matthews, J. G. (2014). The effects of lebrikizumab in patients with mild asthma following whole lung allergen challenge. Clinical & Experimental Allergy, 44(1), 38-46.

Figure 3 Percentage change in FEV1 from baseline to week 20.

(A) mITT; (B) periostin-high patients; and (C) periostin-low patients.

Noonan, M., Korenblat, P., Mosesova, S., Scheerens, H., Arron, J. R., Zheng, Y.,... & Matthews, J. G. (2013). Dose-ranging study of lebrikizumab in asthmatic patients not receiving inhaled steroids. Journal of Allergy and Clinical Immunology, 132(3), 567-574.

Figure 1 Anti-Human IL13 Antibody (Lebrikizumab) (TAB-219) in ELISA

ELISA analysis of TAB-219 was performed by coating with Recombinant Human IL13.